Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monoclonal antibody-based genetic immunotherapy.

Mireia Pelegrin1, Laurent Gros, Hanna Dreja

  • 1Institute of Molecular Genetics of Montpellier, UMR 5535 / IFR122 CNRS 1919, route de Mende 34293 - Montpellier Cédex 05, France. pelegrin@igm.cnrs-mop.fr

Current Gene Therapy
|September 24, 2004
PubMed
Summary

In vivo production of therapeutic monoclonal antibodies offers an alternative to traditional intravenous injections. This gene/cell therapy approach aims to overcome limitations for treating chronic diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive analysis of neutrophil immunomodulatory properties and FcR dynamics in HIV-1 infection and therapy.

iScience·2026
Same author

Editorial: New avenues for the development of advanced immunotherapies: capitalizing on studies of the B and T cell receptor repertoire.

Frontiers in immunology·2025
Same author

FSTL3 is a biomarker of poor prognosis and associated with immunotherapy resistance in ovarian cancer.

Journal of experimental & clinical cancer research : CR·2025
Same author

Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches.

Current opinion in HIV and AIDS·2025
Same author

Targeting SUMOylation Triggers IFN-β-dependent Activation of Patient and Allogenic NK Cells in Preclinical Models of Acute Myeloid Leukemia.

Molecular cancer therapeutics·2025
Same author

Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease.

PloS one·2025

Area of Science:

  • Biotechnology
  • Immunology
  • Gene Therapy

Background:

  • Monoclonal antibodies are vital for treating diseases like cancer and autoimmune disorders.
  • Intravenous antibody administration faces challenges including high costs, hospital requirements, and side effects.
  • Limitations of current antibody treatments hinder widespread clinical application for chronic conditions.

Purpose of the Study:

  • To review advancements in gene and cell therapies for in vivo monoclonal antibody production.
  • To explore alternatives to conventional antibody administration for chronic disease management.
  • To highlight the potential of in vivo antibody generation for therapeutic applications.

Main Methods:

  • Review of recent developments in gene/cell therapy for in vivo antibody production.

Related Experiment Videos

  • Analysis of strategies for systemic delivery of therapeutically produced antibodies.
  • Examination of methods to overcome limitations of intravenous antibody administration.

    • Main Results:

    • In vivo antibody production via gene/cell therapy presents a viable alternative to intravenous injections.
    • This approach may reduce costs and side effects associated with traditional antibody treatments.
    • Continuous, low-level antibody delivery could prevent immune responses and improve bioavailability.

    Conclusions:

    • Gene and cell therapies hold significant promise for in vivo monoclonal antibody production.
    • In vivo antibody generation offers a potential solution for long-term treatment of chronic diseases.
    • This strategy could enhance therapeutic efficacy and patient compliance for monoclonal antibody treatments.